Description

Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels[1].—Cancer-programmed cell death–C82H119N21O34S3—-[1]Pippa N, et al. Advanced nanocarriers for an antitumor peptide. Journal of nanoparticle research, 2013, 15(11): 1-13. –848084-83-3–2039.14—-OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)=O)NC([C@H](CSCNC(C)=O)NC([C@H]([C@H](O)C)NC([C@H](CSCNC(C)=O)NC([C@H]([C@H](O)C)NC([C@H](CCC(O)=O)NC([C@H](CSCNC(C)=O)NC([C@H](CC(N)=O)NC([C@H](CC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](CCC(N)=O)NC([C@@H](NC([C@@H](N)CCC(O)=O)=O)CC2=CNC3=CC=CC=C23)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cancer–10 mM in DMSO–Apoptosis—-Apoptosis–Peptides